Dry powder for inhalation
A dry powder formulation of nintedanib with tailored particle sizes addresses the low bioavailability and side effects of oral administration, enhancing therapeutic efficacy for fibrotic diseases through inhalation delivery.
Patent Information
- Application Number
- PCT/KR2026/096323
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-09
- Filing Date
- 2026-04-27
- Publication Date
- 2026-11-12
AI Technical Summary
Nintedanib, a tyrosine kinase inhibitor, has low bioavailability and causes gastrointestinal side effects when administered orally, limiting its effectiveness in treating fibrotic diseases like idiopathic pulmonary fibrosis and systemic sclerosis-associated interstitial lung disease.
A dry powder formulation containing nintedanib or its pharmaceutically acceptable salts, with specific particle size distributions for both the active ingredient and carrier, optimized for inhalation delivery to improve bioavailability and reduce side effects.
The dry powder formulation enhances nintedanib's bioavailability and reduces gastrointestinal side effects, effectively treating fibrotic diseases by delivering the drug to deep lung regions with minimal adverse reactions.
Smart Images

Figure KR2026096323_12112026_PF_FP_ABST
Abstract
Description
Dry powder for inhalation
[0001] The present invention relates to a dry powder for inhalation containing nintedanib.
[0002] The present disclosure claims the benefit of priority based on Korean Patent Application No. 10-2025-0060736 filed on May 9, 2025, and all contents of Korean Patent Application No. 10-2025-0060736 are incorporated by reference into the present disclosure.
[0003]
[0004] Nintedanib is a small molecule tyrosine kinase inhibitor (TKI) that targets fibrous growth factor receptors such as Platelet-Derived Growth Factor Receptor (PDGFR), Fibroblast Growth Factor Receptor (FGFR), and Vascular Endothelial Growth Factor Receptor (VEGFR). Nintedanib is effective for the treatment of idiopathic pulmonary fibrosis, delaying the decline in lung function in patients with systemic sclerosis-associated interstitial lung disease, and treating chronic fibrotic interstitial lung disease exhibiting a progressive phenotype; it is administered as an oral formulation (product name: Ofev soft capsules). However, when administered orally, nintedanib has low bioavailability and causes side effects such as gastrointestinal disorders.
[0005] The problem that the technical concept of the present invention aims to solve is to provide a dry powder for inhalation containing nintedanib.
[0006] Some embodiments of the present invention capable of solving the above-mentioned problem are as follows.
[0007]
[0008] The dry powder for an inhalation formulation according to some embodiments is:
[0009] An active ingredient which is nintedanib or a pharmaceutically acceptable salt thereof; and
[0010] A carrier in which Dv50 is in the range of 60 μm to 110 μm;
[0011] It may include.
[0012]
[0013] In some embodiments, the Dv10 of the carrier may be in the range of 20 μm to 60 μm.
[0014] In some embodiments, the Dv90 of the carrier may be in the range of 110 μm to 180 μm.
[0015] In some embodiments, the active ingredient may be nintedanib esylate, nintedanib mesylate, nintedanib hydrochloride, nintedanib maleate, or nintedanib sulfate.
[0016] In some embodiments, the active ingredient may be nintedanib esylate.
[0017] In some embodiments, the Dv50 of the active ingredient may be in the range of 0.5 μm to 10 μm.
[0018] In some embodiments, the Dv10 of the active ingredient may be in the range of 0.05 μm to 3 μm.
[0019] In some embodiments, the Dv90 of the active ingredient may be in the range of 5 μm to 100 μm.
[0020] In some embodiments, the carrier may be one or more selected from the group consisting of monosaccharides, disaccharides, polysaccharides, polyalcohols and hydrates thereof.
[0021] In some embodiments, the carrier may be one or more selected from the group consisting of glucose, arabinose, lactose, maltose, sucrose, starch, dextrin, dextran, sorbitol, mannitol, xylitol and hydrates thereof.
[0022] In some embodiments, the carrier may be lactose or lactose hydrate.
[0023] In some embodiments, based on 100 parts by weight of the dry powder for the inhalation formulation, the active ingredient may be included in an amount of 3 to 25 parts by weight and the carrier may be included in an amount of 75 to 97 parts by weight.
[0024] In some embodiments, the carrier may be a mixture of two or more sub-carriers having different particle size distributions.
[0025] In some embodiments, the carrier comprises a first sub-carrier and a second sub-carrier, and the Dv50 of the first sub-carrier may be in the range of 20 μm to 140 μm and the Dv50 of the second sub-carrier may be in the range of 1 μm to 10 μm.
[0026] In some embodiments, based on 100 parts by weight of the dry powder for the inhalation formulation, the active ingredient may be included in an amount of 3 to 25 parts by weight, the first sub-carrier in an amount of 70 to 95 parts by weight, and the second sub-carrier in an amount of 0.5 to 5 parts by weight.
[0027] The dry powder for inhalation according to some embodiments of the present invention may have a therapeutic effect on fibrotic diseases.
[0028] The dry powder for inhalation according to some embodiments of the present invention may have therapeutic effects for idiopathic pulmonary fibrosis, delaying the decline in lung function in patients with systemic sclerosis-associated interstitial lung disease, and treating chronic fibrotic interstitial lung disease exhibiting a progressive phenotype.
[0029] The dry powder for inhalation according to some embodiments of the present invention can increase the bioavailability of nintedanib and may not cause side effects such as digestive disorders.
[0030] The dry powder for inhalation according to some embodiments of the present invention has a good Fine Particle Fraction (FFF) value, so it can deliver a large amount of drug to deep parts of the lungs.
[0031] The effects of the embodiments of the present invention are not limited to those mentioned above, and other unmentioned effects can be clearly derived and understood by those skilled in the art from the following description. That is, unintended effects resulting from the implementation of the embodiments of the present invention can also be clearly derived and understood by those skilled in the art.
[0032] Figure 1 is a dry powder insufflator used in Experimental Example 1.
[0033] Figure 2 is a graph showing the change in body weight of a mouse.
[0034] Figure 3 is a CT image of a mouse's lung.
[0035] Figure 4 is a graph showing the volume / weight ratio of the mouse lungs.
[0036] Figure 5 is an image of a mouse lung after H&E staining.
[0037] Figure 6 is an image of a mouse lung after Masson's Trichrome staining.
[0038] Figure 7 is a graph showing the collagen-positive area of the lungs of a mouse.
[0039] Figure 8 is a graph showing the results of evaluating the Col1a1 gene expression level of mice relative to the GAPDH gene.
[0040] Figure 9 is a graph showing the results of measuring the aerodynamic particle distribution of Experimental Example 2.
[0041] Figure 10 is a graph showing the results of measuring the aerodynamic particle distribution of Experimental Example 3.
[0042] Figure 11 is a graph showing the results of measuring the aerodynamic particle distribution of Experimental Example 3.
[0043] Terms or words used in this specification should not be interpreted as being limited to their ordinary or dictionary meanings, but should be interpreted in a meaning consistent with the technical concept of the invention, based on the principle that the inventor can appropriately define the meaning of terms or words to best describe his invention.
[0044] In this specification, terms such as “comprising” or “having” are intended to specify the existence of the features, numbers, steps, actions, components, parts, or combinations thereof described in the specification, and should not be understood as precluding the existence or addition of one or more other features, numbers, steps, actions, components, parts, or combinations thereof.
[0045] In describing the present invention, if it is determined that a detailed description of a known configuration or function may obscure the essence of the invention, such detailed description is omitted.
[0046]
[0047] The dry powder for an inhalation formulation according to exemplary embodiments may contain an active pharmaceutical ingredient (API) that is nintedanib or a pharmaceutically acceptable salt thereof.
[0048] A dry powder for an inhalation formulation according to exemplary embodiments may be used for the treatment of fibrotic diseases. In the present disclosure, fibrotic disease refers to a group of diseases in which abnormal fibrosis occurs in tissues or organs. Fibrotic diseases may include fibrosis related to lung diseases such as chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis; asthma-related fibrosis such as fibrosis and remodeling of airways and lung tissues due to asthma; fibrosis related to rheumatic diseases; fibrosis related to liver diseases such as virus-induced cirrhosis such as hepatitis C; radiation-induced fibrosis; fibrosis related to vascular diseases such as restenosis and fibrosis after angioplasty; fibrosis related to kidney diseases such as renal fibrosis due to chronic glomerulonephritis and hypertension; fibrosis related to skin diseases such as fibrosis of the skin such as scleroderma, sarcoidosis, and systemic lupus erythematosus; and fibrosis related to scar and wound healing.
[0049] The dry powder for inhalation formulation according to exemplary embodiments may be used for the treatment of idiopathic pulmonary fibrosis, the treatment of chronic fibrotic interstitial lung disease exhibiting a progressive phenotype and delayed decline in lung function in patients with systemic sclerosis-associated interstitial lung disease. In this disclosure, the term "treatment" includes all of the following: reversing, alleviating, suppressing, preventing, and treating a disorder or disease, or the progression of one or more symptoms of a disorder or disease.
[0050] Nintedanib is a compound represented by the chemical formula 1 below.
[0051] [Chemical Formula 1]
[0052]
[0053] Pharmaceutically acceptable salts of nintedanib are not particularly limited as long as they can improve the in vivo absorption rate and / or in vivo stability of nintedanib. Pharmaceutically acceptable salts of nintedanib may be nintedanib esylate, nintedanib mesylate, nintedanib hydrochloride, nintedanib maleate, or nintedanib sulfate. Pharmaceutically acceptable salts of nintedanib may be nintedanib esylate.
[0054] In exemplary embodiments, the Dv10 of the active ingredient may be in the range of about 0.05 µm to about 3 µm. In exemplary embodiments, the Dv50 of the active ingredient may be in the range of about 0.5 µm to about 10 µm. In exemplary embodiments, the Dv90 of the active ingredient may be in the range of about 5 µm to about 100 µm. The particle size distribution of the active ingredient may be measured according to ISO 13320:2009. The particle size distribution of the active ingredient may be measured before mixing with the carrier. As the Dv10, Dv50, and / or Dv90 of the active ingredient become smaller, the proportion of dry powder reaching the peripheral parts of the lungs may increase. If the Dv10, Dv50, and / or Dv90 of the active ingredient are too small, problems such as aggregation, reduced mixing uniformity, and reduced stability may occur. The particle size distribution of the active ingredient can be controlled through methods such as jet milling, ball milling, spray drying, cryogenic milling, wet milling, and ultrasonic milling.
[0055] In exemplary embodiments, the Dv10 of the active ingredient may be about 2.5 μm or less, about 2 μm or less, about 1.5 μm or less, about 1 μm or less, or about 0.7 μm or less. In exemplary embodiments, the Dv10 of the active ingredient may be about 0.1 μm or more, about 0.2 μm or more, about 0.3 μm or more, or about 0.4 μm or more.
[0056] In exemplary embodiments, the Dv50 of the active ingredient may be about 9 μm or less, about 8 μm or less, about 7 μm or less, about 6 μm or less, about 5 μm or less, about 4 μm or less, or about 3.5 μm or less. In exemplary embodiments, the Dv50 of the active ingredient may be about 1 μm or more, about 1.5 μm or more, about 2 μm or more, or about 2.5 μm or more.
[0057] In exemplary embodiments, the Dv90 of the active ingredient may be about 50 μm or less, about 20 μm or less, about 10 μm or less, about 9 μm or less, or about 8 μm or less. In exemplary embodiments, the Dv90 of the active ingredient may be about 5.5 μm or more, about 6 μm or more, about 6.5 μm or more, or about 7 μm or more.
[0058] The dry powder for an inhalation formulation according to exemplary embodiments may comprise a carrier. The particle size distribution of the carrier may be measured according to ISO 13320:2009. The particle size distribution of the carrier may be measured before being mixed with the active ingredient. In exemplary embodiments, the carrier may be a single carrier having a specific particle size distribution. In exemplary embodiments, the carrier may be a mixture of two or more sub-carriers having different particle size distributions. In this case, the particle size distribution of the carrier may be measured after the two or more sub-carriers are mixed. As one example, the Dv10 of a carrier mixed with 10.75 mg of a first sub-carrier (Dv10: 33 μm, Dv50: 83 μm, Dv90: 154 μm) and 0.25 mg of a second sub-carrier (Dv50: 5, Dv90: 10) may be approximately 40.2 μm, Dv50 approximately 88 μm, and Dv90 approximately 159 μm.
[0059] In exemplary embodiments, the Dv10 of the carrier may be in the range of about 20 μm to about 60 μm. In exemplary embodiments, the Dv50 of the carrier may be in the range of about 60 μm to about 110 μm. In exemplary embodiments, the Dv90 of the carrier may be in the range of about 110 μm to about 180 μm. If the Dv10, Dv50, and / or Dv90 of the carrier fall outside the above ranges, fluidity, stability, dispersibility, waste deposition rate, etc. may be reduced.
[0060] In exemplary embodiments, the Dv10 of the carrier may be about 25 μm or more, about 30 μm or more, about 35 μm or more, or about 40 μm or more. In exemplary embodiments, the Dv10 of the carrier may be about 55 μm or less, or about 50 μm or less.
[0061] In exemplary embodiments, the Dv50 of the carrier may be about 65 μm or more, about 70 μm or more, about 75 μm or more, about 80 μm or more, or about 85 μm or more. In exemplary embodiments, the Dv50 of the carrier may be about 105 μm or less, about 100 μm or less, or about 95 μm or less.
[0062] In exemplary embodiments, the Dv90 of the carrier may be about 115 μm or more, about 120 μm or more, or about 125 μm or more. In exemplary embodiments, the Dv90 of the carrier may be about 175 μm or less, about 170 μm or less, about 165 μm or less, about 160 μm or less, about 155 μm or less, about 150 μm or less, about 145 μm or less, about 140 μm or less, or about 135 μm or less.
[0063] In exemplary embodiments, the carrier may include a first sub-carrier and a second sub-carrier. The particle size of the first sub-carrier may be generally larger than the particle size of the second sub-carrier. The dry powder for an inhalation formulation according to exemplary embodiments may optimize fluidity, stability, dispersibility, lung deposition rate, etc. by including a first sub-carrier and a second sub-carrier with different particle sizes. The particle size distribution of each of the first sub-carrier and the second sub-carrier may be measured according to ISO 13320:2009. The particle size distribution of each of the first sub-carrier and the second sub-carrier may be measured before the first sub-carrier and the second sub-carrier are mixed. The Dv10 of the first sub-carrier may be larger than the Dv10 of the second sub-carrier. The Dv50 of the first sub-carrier may be larger than the Dv50 of the second sub-carrier. The Dv90 of the first sub-carrier may be larger than the Dv90 of the second sub-carrier.
[0064] In exemplary embodiments, Dv10 of the first sub-carrier may be in the range of about 10 μm to about 50 μm. In exemplary embodiments, Dv10 of the first sub-carrier may be about 15 μm or more, about 20 μm or more, about 25 μm or more, or about 30 μm or more. In exemplary embodiments, Dv10 of the first sub-carrier may be about 45 μm or less, about 40 μm or less, or about 35 μm or less.
[0065] In exemplary embodiments, the Dv50 of the first sub-carrier may be in the range of about 20 μm to about 140 μm. In exemplary embodiments, the Dv50 of the first sub-carrier may be about 30 μm or more, about 40 μm or more, about 50 μm or more, about 60 μm or more, about 70 μm or more, or about 80 μm or more. In exemplary embodiments, the Dv50 of the first sub-carrier may be about 130 μm or less, about 120 μm or less, about 110 μm or less, about 100 μm or less, or about 90 μm or less.
[0066] In exemplary embodiments, the Dv90 of the first sub-carrier may be in the range of about 100 μm to about 200 μm. In exemplary embodiments, the Dv90 of the first sub-carrier may be about 110 μm or more, about 120 μm or more, about 130 μm or more, about 140 μm or more, or about 150 μm or more. In exemplary embodiments, the Dv90 of the first sub-carrier may be about 190 μm or less, about 180 μm or less, about 170 μm or less, or about 160 μm or less.
[0067] In exemplary embodiments, the Dv50 of the second sub-carrier may be in the range of about 1 μm to about 10 μm. In exemplary embodiments, the Dv50 of the second sub-carrier may be about 2 μm or more, about 3 μm or more, or about 4 μm or more. In exemplary embodiments, the Dv50 of the second sub-carrier may be about 9 μm or less, about 8 μm or less, about 7 μm or less, or about 6 μm or less.
[0068] In exemplary embodiments, the Dv90 of the second sub-carrier may be in the range of about 5 μm to about 20 μm. In exemplary embodiments, the Dv90 of the second sub-carrier may be about 6 μm or more, about 7 μm or more, about 8 μm or more, or about 9 μm or more. In exemplary embodiments, the Dv90 of the second sub-carrier may be about 19 μm or less, about 18 μm or less, about 17 μm or less, about 16 μm or less, about 15 μm or less, about 14 μm or less, about 13 μm or less, about 12 μm or less, or about 11 μm or less.
[0069] In exemplary embodiments, the carrier may include a first sub-carrier, a second sub-carrier, and a third sub-carrier. In exemplary embodiments, the carrier may include a first sub-carrier, a second sub-carrier, a third sub-carrier, and a fourth sub-carrier. Thus, the carrier may include three or more sub-carriers having different particle size distributions.
[0070] The type of carrier is not particularly limited. The type of carrier may be selected from those commonly used in the art to which this disclosure belongs. In exemplary embodiments, the carrier may be a monosaccharide, a disaccharide, a polysaccharide, a polyalcohol, or a hydrate thereof. In exemplary embodiments, the carrier may be glucose, arabinose, lactose, maltose, sucrose, starch, dextrin, dextran, sorbitol, mannitol, xylitol, or a hydrate thereof. In exemplary embodiments, the carrier may be lactose or lactose hydrate. The description of the type of sub-carrier is omitted as it is identical to the description of the type of carrier.
[0071] In exemplary embodiments, the dry powder for an inhalation formulation may contain about 3 to about 25 parts by weight of an active ingredient and about 75 to about 97 parts by weight of a carrier, based on 100 parts by weight of the dry powder for an inhalation formulation. Depending on the content of the active ingredient and the carrier, the proportion of the dry powder reaching the peripheral parts of the lungs may vary. In exemplary embodiments, the dry powder for an inhalation formulation may contain about 6 to about 19 parts by weight of an active ingredient and about 81 to about 94 parts by weight of a carrier, or about 7 to about 15 parts by weight of an active ingredient and about 85 to about 93 parts by weight of a carrier, or about 8 to about 12 parts by weight of an active ingredient and about 88 to about 92 parts by weight of a carrier, based on 100 parts by weight of the dry powder for an inhalation formulation.
[0072] In exemplary embodiments, the dry powder for an inhalation formulation may contain about 3 to about 25 parts by weight of an active ingredient based on 100 parts by weight of the dry powder for an inhalation formulation, about 70 to about 95 parts by weight of a first sub-carrier, and about 0.5 to about 5 parts by weight of a second sub-carrier. Depending on the content of the active ingredient, the first sub-carrier, and the second sub-carrier, the proportion of the dry powder reaching the peripheral parts of the lungs may vary. In exemplary embodiments, the dry powder for an inhalation formulation may comprise, based on 100 parts by weight of the dry powder for an inhalation formulation, about 6 parts by weight to about 19 parts by weight of an active ingredient, about 80 parts by weight to about 90 parts by weight of a first sub-carrier, and about 0.5 parts by weight to about 5 parts by weight of a second sub-carrier, or about 7 parts by weight to about 15 parts by weight of an active ingredient, about 83 parts by weight to about 90 parts by weight of a first sub-carrier, and about 1 part by weight to about 3 parts by weight of a second sub-carrier, or about 8 parts by weight to about 12 parts by weight of an active ingredient, about 86 parts by weight to about 90 parts by weight of a first sub-carrier, and about 1.5 parts by weight to about 2.5 parts by weight of a second sub-carrier.
[0073] A unit dose of dry powder for an inhalation formulation according to exemplary embodiments may be about 10 mg to about 15 mg. A unit dose of dry powder for an inhalation formulation according to exemplary embodiments may be filled into one pouch in a dry powder inhaler. In the present disclosure, the unit dose comprises an active ingredient and a carrier.
[0074] A dry powder for an inhalation formulation according to exemplary embodiments may consist of an active ingredient and a carrier.
[0075]
[0076] Preparation Example
[0077] Dry powders with nintedanib esylate and lactose content as shown in Table 1 below were prepared.
[0078]
[0079] Preparation Example 1 Preparation Example 2 Preparation Example 3 Nintedanib esylate 22 μg 44 μg 0 μg Lactose 2978 μg 2956 μg 3000 μg Total 3000 μg 3000 μg 3000 μg
[0080] Experimental Example 1: Non-clinical test of nintedanib dry powder
[0081] The dry powders of Preparation Examples 1 to 3 were administered to 8-week-old male experimental mice (body weight approx. 22 g) of the C57BL / 6J strain treated with PHMG (Polyhexamethylene guanidine) using the dry powder insufflator of Fig. 1.
[0082] In FIGS. 2 to 8, the control example is an 8-week-old male experimental mouse of the C57BL / 6J lineage that was not administered dry powder and was not treated with PHMG.
[0083] Figure 2 is a graph showing the change in body weight of a mouse. Looking at Figure 2, it can be seen that the body weight of the mouse is restored when Preparation Examples 1 and 2 are administered.
[0084] Figure 3 is a CT image of the lungs of a mouse. Figure 3 shows that the lungs of mice administered Preparation Examples 1 and 2 showed less fibrosis compared to the lungs of mice administered Preparation Example 3. Figure 3 also shows that the lungs of mice administered Preparation Examples 1 and 2 were more similar to the control example than the lungs of mice administered Preparation Example 3.
[0085] Figure 4 is a graph showing the lung volume-to-weight ratio of mice. Looking at Figure 4, it can be seen that the lung volume-to-weight ratio of mice administered Preparation Examples 1 and 2 is higher than that of mice administered Preparation Example 3. Looking at Figure 4, it can be seen that the lung volume-to-weight ratio of mice administered Preparation Examples 1 and 2 is more similar to the lung volume-to-weight ratio of the control example than that of mice administered Preparation Example 3.
[0086] Figure 5 is an image of the mouse lungs after H&E staining. Figure 5 shows that the lungs of mice administered Preparation Examples 1 and 2 showed less fibrosis compared to the lungs of mice administered Preparation Example 3. Figure 5 also shows that the lungs of mice administered Preparation Examples 1 and 2 were more similar to the control example than the lungs of mice administered Preparation Example 3.
[0087] Figure 6 is an image of the mouse lungs after Masson's Trichrome staining. Figure 6 shows that the lungs of mice administered Preparation Examples 1 and 2 showed less fibrosis compared to the lungs of mice administered Preparation Example 3. Figure 6 also shows that the lungs of mice administered Preparation Examples 1 and 2 were more similar to the control example than the lungs of mice administered Preparation Example 3.
[0088] Figure 7 is a graph showing the collagen-positive area of the lungs of mice. Looking at Figure 7, it can be seen that the collagen-positive area of the lungs of mice administered Preparation Examples 1 and 2 is lower than the collagen-positive area of the lungs of mice administered Preparation Example 3. Looking at Figure 7, it can be seen that the collagen-positive area of the lungs of mice administered Preparation Examples 1 and 2 is more similar to the collagen-positive area of the lungs of the control mice than the collagen-positive area of the lungs of mice administered Preparation Example 3.
[0089] Figure 8 is a graph showing the results of a relative evaluation of the Col1a1 gene expression level in mice based on the GAPDH gene. Looking at Figure 8, it can be seen that the Colla1 / GAPDH of mice administered Preparation Examples 1 and 2 is lower than that of mice administered Preparation Example 3. Looking at Figure 8, it can be seen that the Colla1 / GAPDH of mice administered Preparation Examples 1 and 2 is more similar to that of the control mice than that of the mice administered Preparation Example 3.
[0090] In summary, the above information indicates that nintedanib dry powder has therapeutic effects on lung disease-related fibrosis, asthma-related fibrosis, etc. when administered transvaginally.
[0091]
[0092] Examples 1 to 3
[0093] Nintedanib esylates (Dv10: 0.8 μm, Dv50: 3.8 μm, Dv90: 8.4 μm) and a carrier (lactose, Dv10: 45 μm, Dv50: 90 μm, Dv90: 130 μm) were sieved through a 50 mesh sieve and mixed. The content of nintedanib esylates and carriers is as shown in Table 2 below.
[0094]
[0095] Example 1 Example 2 Example 3 Nintedanib esylate 0.60 mg (5 parts by weight) 1.20 mg (10 parts by weight) 2.40 mg (20 parts by weight) Carrier 11.60 mg (95 parts by weight) 11.00 mg (90 parts by weight) 9.80 mg (80 parts by weight) Total 12.20 mg (100 parts by weight) 12.20 mg (100 parts by weight) 12.20 mg (100 parts by weight)
[0096] Examples 4 to 6
[0097] A carrier was prepared by mixing a first sub-carrier (lactose, Dv10: 33 μm, Dv50: 83 μm, Dv90: 154 μm) and a second sub-carrier (lactose, Dv50: 5 μm, Dv90: 10 μm). Nintedanib esylate (Dv10: 0.8 μm, Dv50: 3.8 μm, Dv90: 8.4 μm) and the carrier were mixed after sieving through a 50 mesh sieve. The content of nintedanib esylate, the first sub-carrier, the second sub-carrier, and the carrier is as shown in Table 3 below.
[0098]
[0099] Example 4 Example 5 Example 6 Nintedanib esylate 0.60 mg (5 parts by weight) 1.20 mg (10 parts by weight) 2.40 mg (20 parts by weight) Carrier 1st sub-carrier 11.60 mg (95 parts by weight) 11.35 mg (93 parts by weight) 11.00 mg (90 parts by weight) 10.75 mg (88 parts by weight) 9.80 mg (80 parts by weight) 9.55 mg (78 parts by weight) 2nd sub-carrier 0.25 mg (2 parts by weight) 0.25 mg (2 parts by weight) 0.25 mg (2 parts by weight) Total 12.20 mg (100 parts by weight) 12.20 mg (100 parts by weight) 12.20 mg (100 parts by weight)
[0100] Example 7
[0101] A carrier was prepared by mixing a first sub-carrier (lactose, Dv10: 33 μm, Dv50: 83 μm, Dv90: 154 μm) and a second sub-carrier (lactose, Dv50: 5 μm, Dv90: 10 μm). Nintedanib esylate (Dv10: 0.6 μm, Dv50: 3.0 μm, Dv90: 7.4 μm) and the carrier were mixed after sieving through a 50 mesh sieve. The content of nintedanib esylate, the first sub-carrier, the second sub-carrier, and the carrier is as shown in Table 4 below.
[0102]
[0103] Example 7 Nintedanib esylate 1.20 mg (10 parts by weight) Carrier 1st sub-carrier 11.00 mg (90 parts by weight) 10.75 mg (88 parts by weight) 2nd sub-carrier 0.25 mg (2 parts by weight) Total 12.20 mg (100 parts by weight)
[0104] Experimental Example 2: Measurement of Aerodynamic Particle Distribution 1
[0105] Activar of Korea United Pharmaceutical Co., Ltd. ® The aerodynamic particle distribution of Examples 1 to 6 was measured using [a specific method]. The flow rate was set to 90 LPM. The measurement results are shown in Fig. 9. Fig. 9 shows that the aerodynamic particle distribution of Examples 1, 2, 4, and 5 is superior to that of Examples 3 and 6, and considering the content of nintedanib esylate, the aerodynamic particle distribution of Examples 2 and 5 is the best.
[0106]
[0107] Experimental Example 3: Measurement of Aerodynamic Particle Distribution 2
[0108] Korea United Pharmaceutical Co., Ltd.'s Activar by varying the flow rate to 30 LPM, 60 LPM, and 90 LPM ® The aerodynamic particle distribution of Example 5 was measured using [the device / tool]. The measurement results are shown in Fig. 10.
[0109] Korea United Pharmaceutical Co., Ltd.'s Activar by varying the flow rate to 30 LPM, 60 LPM, and 90 LPM ® The aerodynamic particle distribution of Example 7 was measured using [the device / tool]. The measurement results are shown in Fig. 11.
[0110] Comparing Figures 10 and 11, it can be seen that the aerodynamic particle distribution of Example 7, in which the particle size of nintedanib esylate is generally smaller than that of Example 5, is superior to the aerodynamic particle distribution of Example 5.
[0111]
[0112] Experimental Example 4: Measurement of Aerodynamic Particle Distribution 3
[0113] The measurement results of FPD (Fine Particle Dose), FPF (Fine Particle Fraction), MMAD (Mass Median Aerodynamic Diameter), and GSD (Geometric Standard Deviation) for Examples 2, 5, and 7 are as shown in Table 5 below.
[0114]
[0115] Example 2 Example 5 Example 7 FPD (μg) 3 10.7 3 16.3 4 28.6 FPD (based on 5 μm) (%) 30.8 3 1.1 4 1.9 mm ADD (μm) 4.8 4.9 3.6 GSD 2.0 2.0 1.9
[0116] Looking at Table 5, it can be seen that the aerodynamic particle distribution of Example 7, in which the particle size of nintedanib esylate is generally smaller compared to Examples 2 and 5, is superior to the aerodynamic particle distribution of Examples 2 and 5.
[0117] The above description is merely for illustrative purposes only. The scope of the present invention shall be interpreted by the claims, and all technical ideas within the scope equivalent or equivalent thereto shall be interpreted as being included within the scope of the present invention.
Claims
1. An active ingredient which is nintedanib or a pharmaceutically acceptable salt thereof; and A carrier in which Dv50 is in the range of 60 μm to 110 μm; Dry powder for inhalation formulations containing 2. In Paragraph 1, The Dv10 of the above carrier is a dry powder for an inhalation formulation in the range of 20 μm to 60 μm.
3. In Paragraph 1, The Dv90 of the above carrier is a dry powder for an inhalation formulation in the range of 110 μm to 180 μm.
4. In Paragraph 1, The above active ingredient is a dry powder for an inhalation formulation, which is nintedanib esylate, nintedanib mesylate, nintedanib hydrochloride, nintedanib maleate, or nintedanib sulfate.
5. In Paragraph 1, The above active ingredient is a dry powder for an inhalation formulation, which is nintedanib esylate.
6. In Paragraph 1, The Dv50 of the above active ingredient is a dry powder for an inhalation formulation in the range of 0.5 μm to 10 μm.
7. In Paragraph 1, The Dv10 of the above active ingredient is a dry powder for an inhalation formulation in the range of 0.05 μm to 3 μm.
8. In Paragraph 1, The Dv90 of the above active ingredient is a dry powder for an inhalation formulation in the range of 5 μm to 100 μm.
9. In Paragraph 1, The above carrier is a dry powder for an inhalation formulation selected from one or more of the group consisting of monosaccharides, disaccharides, polysaccharides, polyalcohols, and hydrates thereof.
10. In Paragraph 1, The above carrier is a dry powder for an inhalation formulation selected from one or more of the group consisting of glucose, arabinose, lactose, maltose, sucrose, starch, dextrin, dextran, sorbitol, mannitol, xylitol, and hydrates thereof.
11. In Paragraph 1, The above carrier is a dry powder for an inhalation formulation, which is lactose or lactose hydrate.
12. In Paragraph 1, Based on 100 parts by weight of the dry powder for the above inhalation formulation, It comprises 3 to 25 parts by weight of the above active ingredient, and A dry powder for an inhalation formulation comprising 75 to 97 parts by weight of the above carrier.
13. In Paragraph 1, The above carrier is a dry powder for an inhalation formulation in which two or more sub-carriers having different particle size distributions are mixed.
14. In Paragraph 13, The above carrier includes a first sub-carrier and a second sub-carrier, and The Dv50 of the first sub-carrier is in the range of 20 μm to 140 μm, and The Dv50 of the second sub-carrier above is a dry powder for an inhalation formulation in the range of 1 μm to 10 μm.
15. In Paragraph 14, Based on 100 parts by weight of the dry powder for the above inhalation formulation, It comprises 3 to 25 parts by weight of the above active ingredient, and The above first sub-carrier comprises 70 to 95 parts by weight, and A dry powder for an inhalation formulation comprising 0.5 to 5 parts by weight of the second sub-carrier.
